Abstract

This project is to continue research on the use of anticancer antibodies labeled with radionuclides for cancer detection and localization by external scintigraphy. New antibodies developed against colorectal, lung, liver and other tumors will be evaluated experimentally and clinically as Tc-99m imaging agents, using a new Tc-99m direct labeling method. Radioimmunotherapy with murine Mabs, human Mabs, humanized MAbs and single- chain antibodies labeled with I-131, Y-90, or Re-186/188 will be pursued in animal models and subsequently in clinical trials. Promising lymphoma radioimmunotherapy with a new B-cell lymphoma MAb labeled with I-131 will continue. Other projects to be pursued include the use of a new lung metastatic model of human colonic cancer in nude mice to assess the effects of adjuvant radioimmunotherapy on survival; relationships of tumor and vascular physiology to antibody and accretion; reduction of myelotoxicity with cytokines.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA039841-11
Application #
2089985
Study Section
Special Emphasis Panel (SRC (88))
Project Start
1985-07-01
Project End
1999-04-30
Budget Start
1995-06-15
Budget End
1996-04-30
Support Year
11
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
City
Belleville
State
NJ
Country
United States
Zip Code
07950

  Publications

Goldenberg, David M (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52:281-96
Waskewich, Chris; Blumenthal, Rosalyn D; Li, Honglan et al. (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029-33
Goldenberg, David M (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713
Newton, D L; Hansen, H J; Mikulski, S M et al. (2001) Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97:528-35
Ong, G L; Elsamra, S E; Goldenberg, D M et al. (2001) Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 7:192-201
Gold, D V; Cardillo, T; Goldenberg, D M et al. (2001) Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol 39:147-54
Ochakovskaya, R; Osorio, L; Goldenberg, D M et al. (2001) Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res 7:1505-10
Ong, G L; Mattes, M J (2000) Limitations in the use of low pH extraction to distinguish internalized from cell surface-bound radiolabeled antibody. Nucl Med Biol 27:571-5
Goldenberg, D M; Abdel-Nabi, H; Sullivan, C L et al. (2000) Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer 89:104-15
Juweid, M E; Hajjar, G; Stein, R et al. (2000) Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 41:93-103

Showing the most recent 10 out of 223 publications